Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Praxis Precision Medicines (PRAX) over the last 3 years, with Dec 2024 value amounting to $483.1 million.

  • Praxis Precision Medicines' Liabilities and Shareholders Equity fell 4.77% to $396.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 51.47%. This contributed to the annual value of $483.1 million for FY2024, which is 449.31% up from last year.
  • Per Praxis Precision Medicines' latest filing, its Liabilities and Shareholders Equity stood at $483.1 million for FY2024, which was up 449.31% from $87.9 million recorded in FY2023.
  • Over the past 5 years, Praxis Precision Medicines' Liabilities and Shareholders Equity peaked at $483.1 million during FY2024, and registered a low of $87.9 million during FY2023.
  • For the 3-year period, Praxis Precision Medicines' Liabilities and Shareholders Equity averaged around $228.7 million, with its median value being $115.1 million (2022).
  • In the last 5 years, Praxis Precision Medicines' Liabilities and Shareholders Equity dropped by 23.61% in 2023 and then surged by 449.31% in 2024.
  • Over the past 3 years, Praxis Precision Medicines' Liabilities and Shareholders Equity (Yearly) stood at $115.1 million in 2022, then decreased by 23.61% to $87.9 million in 2023, then surged by 449.31% to $483.1 million in 2024.